

# **Review article**

# Mechanistic targets for the ablation of atrial fibrillation

Junaid A.B. Zaman<sup>1,2</sup>, Tina Baykaner<sup>1,3</sup>, Amir A. Schricker<sup>3</sup>, David E. Krummen<sup>3</sup>, Sanjiv M. Narayan<sup>1\*</sup>

# ABSTRACT

The mechanisms responsible for sustaining atrial fibrillation are a key debate in cardiovascular pathophysiology, and directly influence the approach to therapy including ablation Clinical and basic studies have split AF mechanisms into two basic camps: 'spatially distributed disorganization' and 'localized sources'. Recent data suggest that these mechanisms can also be separated by the method for mapping – with nearly all traditional electrogram analyses showing spatially distributed disorganization and nearly all optical mapping studies showing localized sources We will review this dichotomy in light of these recently identified differences in mapping, and in the context of recent clinical studies in which localized ablation has been shown to impact AF, also lending support to the localized source hypothesis. We will conclude with other concepts on mechanism-based ablation and areas of ongoing research that must be addressed to continue improving our knowledge and treatment of AF.

http://dx.doi.org/ 10.21542/gcsp.2017.7

Submitted: 1 September 2015 Accepted: 29 November 2015 © 2017 The Author(s), licensee Magdi Yacoub Institute. This is an open access article distributed under the terms of the Creative Commons Attribution license CC BY-4.0, which permits unrestricted use, distribution and reproduction in any medium, provided the original work is properly cited.

This article was originally published, as an unapproved proof, on the QScience.com platform in 2015. It is republished here, with author corrections, under the terms of the Creative Commons Attribution licence CC BY-3.0.

Cite this article as: Zaman JAB, Baykaner T, Schricker AA, Krummen DE, Narayan SM. Mechanistic targets for the ablation of atrial fibrillation, Global Cardiology Science and Practice 2017:7 http://dx.doi.org/10.21542/gcsp.2017.7

<sup>1</sup> Stanford University, Palo Alto, California

OPEN ACCESS

- <sup>2</sup> Imperial College, University of London, United Kingdom
- <sup>3</sup> University of California, San Diego, California
- \*Email: sanjiv1@stanford.edu

## **1. INTRODUCTION**

Atrial fibrillation (AF) affects 30 million people globally<sup>1</sup> making it the commonest sustained heart rhythm disorder It is also a major cause of hospitalizations, stroke and death. Therapy is based on drugs or ablation, yet both remain suboptimal due to uncertain mechanisms and drug side-effects

A fundamental mechanistic dichotomy in human atrial (and ventricular) fibrillation is whether disorder is driven by self-sustaining disorganization or by discrete organized processes. Although little overlap exists between each camp, it is increasingly apparent that they may reflect the mapping technique used rather than experimental model of AF or underlying pathophysiology Studies using optical mapping of action potentials, that indicate activation and recovery, mostly show localized sources that drive disorganized activation in fibrillation,<sup>2,3</sup> yet studies using clinical electrograms (surrogates for cellular activation) mostly do not. Understanding how these techniques differ in representing cellular activity in fibrillation may help to advance this crucial mechanistic debate.<sup>4</sup>

This review first briefly outlines the mechanism of fibrillation in animal models described by different mapping techniques.<sup>2</sup> Given the paucity of optical mapping studies of cardiac fibrillation in humans, we will use clinical mapping results to compare and contrast clinical results and discuss mechanistic implications We then highlight clinical data with outcomes of AF ablation that promise patient tailored therapy.

#### 2. MAPPING APPROACHES TO ATRIAL FIBRILLATION

To map fibrillation one must identify atrial activation and repolarization at high temporal and spatial resolution without signal contamination (crosstalk) from adjacent sites. In organized rhythms such as atrial flutter, where all regions activate 1:1, crosstalk may alter activation time at each electrode but overall has minimal importance and so most mapping techniques agree. However, in fibrillation, adjacent tissue regions may reflect unrelated (dissociated) activation at different rates Thus, in fibrillation, crosstalk may contaminate local signals with dissociated far-field detections that may augment, cancel or modify activity and dramatically change mapping. Repolarization information available from optical mapping, monophasic action potentials and other techniques provide data to identify whether given deflections lie within tissue refractoriness (i.e., are far field) or are local.

Optical mapping of voltage-sensitive dyes is often considered the gold standard to map complex arrhythmias.<sup>5</sup> In this technique, light excites voltage sensitive dyes that fluoresce in proportion to membrane potential Each map shows the optical action potential (hence activation and recovery) at multiple sites and successive images represent propagation of the wavefront Optical mapping has recently been used to map AF in human atria.<sup>6</sup> Crucially, optical maps show minimal signal crosstalk – essentially within the small area optically mapped by each image pixel. There has long been a call to apply optical imaging to human AF in order to categorically identify mechanisms.<sup>5</sup> Unfortunately, optical mapping is not feasible in patients *in vivo* due to dye toxicity, motion artifact and the difficulties of imaging through blood. However, there is promising small animal data using *in situ* optical mapping, which may pave the way for *in vivo* studies.<sup>7</sup> Figure 1 illustrates the difference between optical mapping of AF and challenges with electrogram-based methods that we will now outline.

In patients, action potentials (activation and recovery) can be measured with monophasic action potential (MAP) catheters. Extracellular MAPs have been validated against intracellular recordings,<sup>8</sup> with some discussion on their precise origin,<sup>9</sup> but



**Figure 1. Optical mapping addresses limitations of electrogram mapping.** A) Sub-endocardial optical mapping of human atria shows a stable rotor driving AF. Optical action potentials (OAPs) at sites 1–4 show activation and recovery over multiple sequential cycles. Note the complex fractionated electrograms (Cath 1 EG) despite the organized action potential signals. From [6]. B) Human AF showing clear and discrete monophasic action potentials on (MAP) catheter yet very complex bipolar electrograms representing far-field wavelet collision. C) Clinical bipoles reveal signals indistinguishable from local activation that actually represents far-field activation on the MAP. Signals in panels B, C greatly complicate AF maps from bipolar signals. From [11].

accurately depict action potentials and their rate dynamics in human atria and ventricles <sup>10,11</sup>, alternans of APD prior to AF<sup>12</sup> and spectral signatures of such traces,<sup>13</sup> which assess substrate in a manner that greatly complements the limitations of electrogram only analyses However, technical difficulties in recording MAPs limit this method in humans to a small number of experienced centers.<sup>14–18</sup>

AF is most commonly mapped clinically using electrograms, that identify activation more than repolarization and were validated for organized rhythms such as supraventricular tachycardias<sup>19–21</sup> where all sites activate in a 1:1 fashion In fibrillation, however, electrograms may show dramatic cross-talk from adjacent sites of undefined area.<sup>11</sup> It is undefined if a 'qS' or 'rR' complex in AF,<sup>22,23</sup> identified by rules developed for non-fibrillatory rhythms, identifies a focal beat or 'non-local' activation respectively - since each site integrates multiple unrelated waves of varying rate, directionality and size with no clear way of discriminating them (Figure 1).<sup>11</sup>

# **3. MECHANISMS OF ATRIAL FIBRILLATION REVEALED BY OPTICAL IMAGING VERSUS ELECTROGRAM MAPPING**

Optical mapping studies of AF reveal that the disorder of AF is driven by localized electrical circuits in the form of spiral wave re-entry or rotors in many species<sup>3,24,25</sup> including diseased human hearts.<sup>6</sup> Spiral wave reentry in Figure 2A<sup>26</sup> forms due to wave curvature and conduction slowing and may anchor at sites of reduced excitability such as fibrosis.<sup>6</sup> From this 'core' (or singularity), waves emanate and breakdown to disorganized activity manifesting as fibrillation on clinical ECGs. Figure 2B shows rotors demonstrated in this way in rabbit ventricular fibrillation.



**Figure 2. Spiral wave re-entry as drivers of cardiac fibrillation.** A) Schematic of spiral wave, showing wavefront curvature as conduction velocity slows towards core (\*), where wavefront meets wave-tail. This indicates the need to map activation and recovery. Action potentials from sites 1–3 show varying APD, allowing re-entry around the unexcited, yet excitable core. From [26]. B) First experimental demonstration of spiral waves in rabbit ventricular fibrillation. Phase is depicted in colour with chirality of spiral wave demarcated by +(clockwise) or –(counter-clockwise). From [2]. C) Activation map of human AF rotor showing circular activation with early-meets-late isochrones (red to blue) and fibrillatory breakdown on the periphery (double white bars). From [68].

Thus, the optical mapping literature shows 'hierarchical' AF mechanisms between a source and disorganization in most preparations and models.<sup>27</sup> Optical mapping also shows transmural differences between endo- and epicardium. When both surfaces are mapped simultaneously, rotors on one surface appear as focal activity on the other.<sup>3,24,25,28</sup> Most recently optical mapping of human AF has revealed stable endocardial rotors that were eliminated by localized ablation, that showed epicardially as focal breakthroughs.<sup>6</sup>

In contrast to optical mapping, nearly all mapping using traditional electrogram rules in AF show complex disorganized activity<sup>29,30</sup> without localized sources. A current subject of study is why traditional electrogram maps differ so dramatically from optical studies, including in human AF,<sup>6</sup> but this may reflect the limitations of traditional electrogram rules in fibrillation,<sup>11,31</sup> the fact that traditional studies mapped only small areas simultaneously (<10% atrial area) and that interventions to prove mechanism (as opposed to bystander) were rarely applied.<sup>22</sup>

Recent approaches to map clinical AF from electrograms has used global real-time mapping, incorporated rate-dependence of human atrial repolarization and conduction, combined with computer modelling using phase analysis to filter far-field signals (FIRM mapping).<sup>32</sup> Such studies have revealed human AF rotors and focal sources (Figure 2C) that may arise in stable areas of  $\approx 2$ cm<sup>2</sup> in right or left atria, where ablation is able to eliminate AF.

These somewhat surprising properties have now been supported by optical mapping of human AF in right<sup>6</sup> and left<sup>33</sup> atria, and preliminary studies show a close correlation between FIRM and simultaneous optical maps in human AF.<sup>34</sup> As described below, these novel approaches to mapping have improved ablation results in several multicenter studies and randomized trials are ongoing.

In summary, an intriguing dichotomy in AF is that the majority of studies that map action potentials optically – the gold standard – show localized sources that drive disorganization Conversely, traditional electrogram maps mostly do not – showing disorganization without sources. Thus, there is an urgent need to perform simultaneous optical and electrogram studies in human AF to explain these differences and, most importantly, to derive electrogram analyses that circumvent the limitations of traditional analyses in fibrillation.<sup>22</sup>

#### 4. CLINICAL OBSERVATIONS IN SUPPORT OF HIERARCHICAL AF ORGANIZATION

One critical question that supports the primary mechanistic role of AF drivers is: how else can we explain the termination of persistent AF, with a globally remodeled substrate, by focal ablation? After anecdotal reports of serendipitous termination of AF by focal intervention,<sup>35,36</sup> acute AF termination has been described systematically after focal ablation of rotors.<sup>32,37,38</sup> Indeed, the multiwavelet reentry model cannot readily reconcile this observation (AF termination by targeted ablation), stable gradients in AF rate,<sup>39</sup> vector,<sup>40</sup> or electrogram shape.<sup>41</sup> In addition, the localized source model is also supported by jumps rather than gradual increases in AF organization by ablation<sup>42</sup> and the fact that more extensive ablation (that should constrain multiple wavelets) does not improve ablation success.<sup>43–45</sup> Recent studies show how localized ablation of a driver can interfere with functional non-uniformities of the human atria to terminate AF to sinus rhythm.<sup>46</sup>

# **5. MANAGEMENT OF ATRIAL FIBRILLATION USING NOVEL MAPPING TARGETS FOR ABLATION**

The first systematic proof of the localized source hypothesis for AF was the CONFIRM (Conventional Ablation With or Without Focal Impulse and Rotor Modulation) trial, used a novel computational mapping approach (FIRM) that interprets electrograms computationally in the context of human repolarization and phase information (Figure 3). Ninety two patients (72% persistent) were assigned prospectively to either conventional ablation or conventional plus rotor (FIRM) guided ablation.<sup>32</sup> Localized sources were present in 97% of cases, each exhibiting 2–3 sources, of which one third lay in the right atrium. Brief FIRM guided ablation at each source in turn translated to higher single procedure freedom (82.4% vs. 44.9%, p < 0.001), confirmed by continuous implantable monitors in most patients, that was maintained on extended 3-year follow-up.<sup>47</sup> Limitations of the CONFIRM trial include the fact that FIRM-guided ablation was performed at one center, that remapping of rotors and focal sources was not possible, and the trial was relatively small.

Several studies outside of the index center now report similar results of FIRM-guided ablation, with single-procedure freedom from AF at  $\approx$ 70–80% in over 400 patients mostly with persistent AF.<sup>48–53</sup> One recent study<sup>54</sup> showed disappointing results lower than PV isolation success at other centers, even though PV isolation was performed As discussed by Jalife et al.,<sup>55</sup> this may represent technical issues since cycle lengths in AF of 250–500ms were reported (dominant frequency 2–4 Hz, too slow for AF), or because basket catheters were inadvertently placed in left ventricle rather than the atria,<sup>56</sup> or because of a challenging patient population As discussed, localized sources from a series of mapping studies including FIRM share similarities to those from optical maps of human AF

Mechanistically, other groups have had some success in identifying rotational circuits in human AF using traditional electrogram analyses.<sup>57,58</sup> The fact that rotational circuits are seen at all by traditional mapping differs from prior reports showing no sources.<sup>22</sup> It remains to be seen if transient rotations seen by surgical<sup>23,59</sup> or body surface mapping<sup>38</sup>



**Figure 3. Immediate and long-term clinical success of localized ablation in human atrial fibrillation.** A) Two left atrial rotors in the superior and inferior left atrial septum. Note progression of activation times (colours) as in Figure 2C. B) Abrupt termination to sinus rhythm during ablation of left inferior septal rotor during first minute of ablation in Shivkumar et al.<sup>37</sup> C) Very long-term freedom from atrial fibrillation (AF) in the CONFIRM trial for FIRM-guided ablation (blue) and conventional ablation (red; P = 0.003) after 1.2  $\pm$  0.4 procedures. D) Very long-term single-procedure freedom from the AF for FIRM-guided ablation. Data show all cases (solid lines, P = 0.002) and patients undergoing their first ablation (dashed lines, P = 0.002) From [47].

studies reflect limitations of electrogram interpretation or rotor instability on the epicardium versus stability on the endocardium.<sup>6</sup>

One interesting contradiction in the body surface literature is that while activation mapping shows transient and rare rotations in AF,<sup>60</sup> phase analyses show rotations consistent with sources/drivers –in the same region over prolonged periods of time where ablation can terminate AF.<sup>38</sup> It is unresolved if this reflects vagaries in marking activation times (difficult in fibrillation) that is not required in phase analysis, or other factors. Technical challenges of source detection for the body surface have been identified, due to small signals, cancellation of phase singularities and amplification of drift<sup>61</sup> that are relevant to this discussion. Notably, localized stable sources from phase analysis appear to agree better with optical mapping data including in humans,<sup>6</sup> and explain AF termination by ablation at these sites.

Overall, there is renewed attention on mechanistic targets in AF after the BOCA and STAR-AF 2 trials, which showed no benefit for widely distributed empirical ablation (stereotypical lines or complex fractionated electrograms) compared to PVI alone.<sup>44,45</sup> This lack of incremental benefit with additional ablation goes against a widely distributed, non-hierarchical mechanism in human persistent AF, favoring a localized hierarchy of AF mechanisms.<sup>62</sup> Other proposed mechanistic targets include ganglionated plexi (Figure 4A),<sup>63</sup> areas with low voltage,<sup>64</sup> fastest activation rates or dominant



**Figure 4. Other considerations for mechanistic ablation in AF.** A) Distribution of ganglionated plexi in the left atrium, with clustering around the PVs. From [69]. B) Left atrial fibrosis imaging may inform ablation strategies. 3D left atrial shell has patchy fibrosis in a Utah Stage IV patient. From [66]. Regardless of targets, a schematic C) of left atrial area (note posterior wall alone is over 30 cm<sup>2</sup>) shows the extensive ablation performed (blue shading) during routine cryoballoon therapy. Note that the shaded area has significant overlap with targets in A) & B). From [67].

frequency<sup>65</sup> and fibrosis (Figure 4B) <sup>66</sup>. As we improve our understanding of the mechanistic targets, so we should also seek to improve lesion delivery. Current platforms such as cryoballoon have the advantage of treating significant amounts of substrate beyond the pulmonary veins (Figure 4C),<sup>67</sup> allowing rapid and effective ablation although obscuring the exact mechanisms of benefit.

## CONCLUSIONS

Atrial fibrillation represents a complex pathophysiological interplay between dynamic and fixed mechanisms. Optical mapping, the gold standard for mapping arrhythmias, typically reveals localized sources for AF that produce disorganization, while studies using traditional electrogram analyses typically do not. Novel mapping techniques such as FIRM have recently shown rotors and focal sources that show similarities to optical mapping studies yet are difficult to explain by the multiwavelet disorder model While promising in early multicenter studies, ongoing randomized clinical trials will define their eventual role in treating AF based on mechanistic targets. It is expected that innovative mechanistic studies in the next few years, centered on optical mapping, will provide substantial insights into treatable and individualized mechanisms for the disease processes currently grouped as 'atrial fibrillation'.

#### **Competing interests**

- Dr. Zaman: Reports no conflicts
- Dr. Baykaner: Reports no conflicts
- Dr. Schricker: Reports no conflicts

Dr. Krummen: Reports consulting work with Topera Inc. Additionally, his Institution has received fellowship support from Medtronic, Boston Scientific, St. Jude Medical and Biotronik.

Dr. Narayan: Dr. Narayan reports being co-inventor on intellectual property owned by the University of California and licensed to Topera Medical, Inc. Dr. Narayan holds equity in Topera. Dr. Narayan also reports having received consulting fees from the American College of Cardiology, St Jude Medical, Medtronic, Uptodate and Janssen Pharmaceuticals.

## Funding

This work was supported in part by a British Heart Foundation Fellowship (FS/14/46/30907) and Fulbright Award to JZ, a HRS Research Fellowship to TB, an ACC-Merck fellowship to AAS, and grants from the National Institutes of Health (HL70529, HL83359, HL103800) to SMN.

# REFERENCES

- [1] Chugh SS, Havmoeller R, Narayanan K, Singh D, Rienstra M, Benjamin EJ, Gillum RF, Kim Y-H, McAnulty JH, Zheng Z-J, Forouzanfar MH, Naghavi M, Mensah GA, Ezzati M, Murray CJL. Worldwide epidemiology of atrial fibrillation: A Global Burden of Disease 2010 Study. *Circulation*. 2014;129:837–847.
- [2] Gray R, Pertsov A, Jalife J. Spatial and temporal organization during cardiac fibrillation. *Nature*. 1998;392:75–78.
- [3] Skanes AC, Mandapati R, Berenfeld O, Davidenko JM, Jalife J. Spatiotemporal periodicity during atrial fibrillation in the isolated sheep heart. *Circulation*. 1998;98:1236–1248.
- [4] Zaman JAB, Peters NS. The rotor revolution: Conduction at the eye of the storm in atrial fibrillation. *Circ Arrhythmia Electrophysiol*. 2014;7:1230–1236.
- [5] Efimov IR, Nikolski VP, Salama G. Optical imaging of the heart. Circ Res. 2004;95:21-33.
- [6] Hansen BJ, Zhao J, Csepe TA, Moore BT, Li N, Jayne LA, Kalyanasundaram A, Lim P, Bratasz A, Powell KA, Simonetti OP, Higgins RSD, Kilic A, Mohler PJ, Janssen PML, Weiss R, Hummel JD, Fedorov VV. Atrial fibrillation driven by micro- anatomic intramural re-entry revealed by simultaneous sub-epicardial and sub-endocardial optical mapping in explanted human hearts. *Eur Heart J*. 2015b;1:12.
- [7] Lee P, Taghavi F, Yan P, Ewart P, Ashley EA, Loew LM, Kohl P, Bollensdorff C, Woods CE. In situ optical mapping of voltage and calcium in the heart. *PLOS ONE*. 2012;7:e42562.
- [8] Franz MR, Chin MC, Sharkey HR, Griffin JC, Scheinman MM. A new single catheter technique for simultaneous measurement of action potential duration and refractory period *in vivo. J Am Coll Cardiol.* 1990;16:878–886.
- [9] Kondo M, Nesterenko V, Antzelevitch C. Cellular basis for the monophasic action potential. Which electrode is the recording electrode? *Cardiovasc Res.* 2004;63:635–644.
- [10] Narayan SM, Franz MR. Quantifying fractionation and rate in human atrial fibrillation using monophasic action potentials: Implications for substrate mapping. *Europace*. 2007;9(Suppl 6):vi89–vi95.
- [11] Narayan SM, Wright M, Derval N, Jadidi A, Forclaz A, Nault I, Miyazaki S, Sacher F, Bordachar P, Clémenty J, Jaïs P, Haïssaguerre M, Hocini M. Classifying fractionated electrograms in human atrial fibrillation using monophasic action potentials and activation mapping: Evidence for localized drivers, rate acceleration, and nonlocal signal etiologies. *Heart Rhythm*. 2011;8:244–253.
- [12] Narayan SM, Bode F, Karasik P, Franz MR. Alternans of atrial action potentials during atrial flutter as a precursor to atrial fibrillation. *Circulation*. 2002;106:1968–1973.
- [13] Lalani GG, Schricker AA, Clopton P, Krummen DE, Narayan SM. Frequency analysis of atrial action potential alternans: A sensitive clinical index of individual propensity to atrial fibrillation. *Circ Arrhythm Electrophysiol.* 2013;6:859–867.
- [14] Vigmond EJ, Leon LJ. Electrophysiological basis of mono-phasic action potential recordings. Med Biol Eng Comput. 1999;37:359–365.
- [15] Coronel R, de Bakker JMT, Wilms-Schopman FJG, Opthof T, Linnenbank AC, Belterman CN, Janse MJ. Monophasic action potentials and activation recovery intervals as measures of ventricular action potential duration: Experimental evidence to resolve some controversies. *Heart Rhythm*. 2006;3:1043–1050.
- [16] Narayan SM, Krummen DE, Kahn AM, Karasik PL, Franz MR. Evaluating fluctuations in human atrial fibrillatory cycle length using monophasic action potentials. *Pacing Clin Electrophysiol*. 2006;29:1209–1218.
- [17] Franz M, Jamal S, Narayan S. The role of action potential alternans in the initiation of atrial fibrillation in humans: A review and future directions. *Europace*. 2012;58–64.
- [18] Krummen DE, Bayer JD, Ho J, Ho G, Smetak MR, Clopton P, Trayanova NA, Narayan SM. Mechanisms for human atrial fibrillation initiation: Clinical and computational studies of repolarization restitution and activation latency. *Circ Arrhythm Electrophysio.* 2012, DOI: 101161/CIRCEP111969022.
- [19] Kalman JM, Olgin JE, Saxon LA, Fisher WG, Lee RJ, Lesh MD. Activation and entrainment mapping defines the tricuspid annulus as the anterior barrier in typical atrial flutter. *Circulation*. 1996;94:398–406.
- [20] Narayan SM, Hassankhani A, Feld GK, Bhargava V. Separating non-isthmus- from isthmus-dependent atrial flutter using wavefront variability. J Am Coll Cardiol. 2005;45:1269–1279.
- [21] Kahn AM, Krummen DE, Feld GK, Narayan SM. Localizing circuits of atrial macroreentry using electrocardiographic planes of coherent atrial activation. *Heart Rhythm*. 2007;4:445–451.
- [22] Allessie MA, de Groot NMS, Houben RPM, Schotten U, Boersma E, Smeets JL, Crijns HJ. Electropathological substrate of long-standing persistent atrial fibrillation in patients with structural heart disease: Longitudinal dissociation. *Circ Arrhythm Electrophysiol*. 2010;3:606–615.

- [23] Lee G, Kumar S, Teh A, Madry A, Spence S, Larobina M, Goldblatt J, Brown R, Atkinson V, Moten S, Morton JB, Sanders P, Kistler PM, Kalman JM. Epicardial wave mapping in human long-lasting persistent atrial fibrillation: Transient rotational circuits, complex wavefronts, and disorganized activity. *Eur Heart J*. 2014;35:86–97.
- [24] Po SS, Li Y, Tang D, Liu H, Geng N, Jackman WM, Scherlag B, Lazzara R, Patterson E. Rapid and stable re-entry within the pulmonary vein as a mechanism initiating paroxysmal atrial fibrillation. *J Am Coll Cardiol*. 2005;45:1871–1877.
- [25] Chou C-C, Chang P-C, Wen M-S, Lee H-L, Chen T-C, Yeh S-J, Wu D. Epicardial ablation of rotors suppresses inducibility of acetylcholine-induced atrial fibrillation in left pulmonary vein-left atrium preparations in a beagle heart failure model. *J Am Coll Cardiol*. 2011;58:158–166.
- [26] Pandit SV, Jalife J. Rotors and the dynamics of cardiac fibrillation. *Circ Res.* 2013;112:849–862.
- [27] Sabouri S, Matene E, Vinet A, Richer L. Simultaneous epicardial and noncontact endocardial mapping of the canine right atrium: Simulation and experiment. *PLOS ONE*. 2014;9:1–11.
- [28] Gutbrod SR, Walton R, Gilbert S, Meillet V, Jais P, Hocini M, Haissaguerre M, Dubois R, Bernus O, Efimov I. Quantification of the transmural dynamics of atrial fibrillation by simultaneous endocardial and epicardial optical mapping in an acute sheep model. *Circ Arrhythmia Electrophysiol*. 2015;8:456–465.
- [29] Groot N de, Houben R, Smeets J, Boersma E, Schotten U, Schalij M, Crijns H, Allessie M. Electropathological substrate of longstanding persistent atrial fibrillation in patients with structural heart diseaseclinical perspective. *Circulation*. 2010;1674–1682.
- [30] Eckstein J, Zeemering S, Linz D, Maesen B, Verheule S, van Hunnik A, Crijns H, Allessie MA, Schotten U. Transmural conduction is the predominant mechanism of breakthrough during atrial fibrillation: Evidence from simultaneous endo-epicardial high-density activation mapping. *Circ Arrhythm Electrophysiol*. 2013;6:334–341.
- [31] Lau DH, Maesen B, Zeemering S, Kuklik P, van Hunnik A, Lankveld TAR, Bidar E, Verheule S, Nijs J, Maessen J, Crijns H, Sanders P, Schotten U. Indices of bipolar complex fractionated atrial electrograms correlate poorly with each other and atrial fibrillation substrate complexity. *Hear Rhythm*. 2015;12:1415–1423.
- [32] Narayan SM, Krummen DE, Shivkumar K, Clopton P, Rappel W-J, Miller JM. Treatment of atrial fibrillation by the ablation of localized sources. *J Am Coll Cardiol*. 2012b;60:628–636.
- [33] Zhao J, Hansen BJ, Csepe TA, Lim P, Hummel JD, Fedorov VV. Integration of high resolution optical mapping and 3D micro-CT imaging to resolve the structural basis of atrial conduction in the human heart. *Circ Arrhythmia Electrophysiol*. 2015;1–7.
- [34] Hansen BJ, Briggs C, Moore BT, Csepe TA, Li N, Zhao J, Garikipati NV, Janssen PM, Mohler PJ, Hummel JD, Fedorov VV. Abstract 18402: Human atrial fibrillation drivers seen simultaneously by focal impulse and rotor mapping and high- resolution optical mapping. *Circulation*. 2015a;132:A18402.
- [35] Herweg B, Kowalski M, Steinberg JS. Termination of persistent atrial fibrillation resistant to cardioversion by a single radiofrequency application. *Pacing Clin Electrophysiol*. 2003;26:1420–1423.
- [36] Tzou WS, Sághy L, Lin D. Termination of persistent atrial fibrillation during left atrial mapping. J Cardiovasc Electrophysiol. 2011;22:1171–1173.
- [37] Shivkumar K, Ellenbogen KA, Hummel John D, Miller JM, Steinberg JS. Acute termination of human atrial fibrillation by identification and catheter ablation of localized rotors and sources: First Multicenter experience of focal impulse and rotor modulation (FIRM) ablation. J Cardiovasc Electrophysiol. 2012;23:1277–1285.
- [38] Haissaguerre Michel, Hocini Meleze, Daly Arnaud, Shah Ashok J, Komatsu Yuki, Yamashita Seigo, Daly Matthew, Amraoui Sana, Zellerhoff Stephan, Picat Marie-Quitterie, Quotb Adam, Jesel Laurence, Lim Han, Ploux Sylvain, Bordachar Pierre, Attuel Guillaume, Meillet Valentin, Ritter Philippe, Derval Nicolas, Sacher Frederic, BernusHubert Cochet, Pierre Jais, Remi Dubois Olivier. Driver domains in persistent atrial fibrillation. *Circulation*. 2014;130:530–538.
- [39] Filgueiras-Rama D, Price NF, Martins RP, Yamazaki M, Avula UMR, Kaur K, Kalifa J, Ennis SR, Hwang E, Devabhaktuni V, Jalife J, Berenfeld O. Long-term frequency gradients during persistent atrial fibrillation in sheep are associated with stable sources in the left atrium. *Circ Arrhythm Electrophysiol*. 2012;1160–1167.
- [40] Gerstenfeld EP, Sahakian AV, Swiryn S. Evidence for transient linking of atrial excitation during atrial fibrillation in humans. *Circulation*. 1992;86:375–382.
- [41] Ng J, Gordon D, Passman RS, Knight BP, Arora R, Goldberger JJ. Electrogram morphology recurrence patterns during atrial fibrillation. *Hear Rhythm*. 2014;11:2027–2034.
- [42] Iravanian S, Langberg JJ. Spatiotemporal organization during ablation of persistent atrial fibrillation. *Heart Rhythm.* 2015, DOI: 10.1016/j.hrthm.2015.04.027.
- [43] Wynn GJ, Das M, Bonnett LJ, Panikker S, Wong T, Gupta D. Efficacy of catheter ablation for persistent atrial fibrillation: A systematic review and meta-analysis of evidence from randomised and non-randomised controlled trials. *Circ Arrhythmia Electrophysiol*. 2014; CIRCEP114001759.
- [44] Verma A, Jiang C, Betts TR, Chen J, Deisenhofer I, Mantovan R, Macle L, Morillo CA, Haverkamp W, Weerasooriya R, Albenque J-P, Nardi S, Menardi E, Novak P, Sanders P. Approaches to catheter ablation for persistent atrial fibrillation. N Engl J Med. 2015;372:1812–1822.
- [45] Wong KCK, Paisey JR, Sopher M, Balasubramaniam R, Jones M, Qureshi N, Hayes CR, Ginks MR. No benefit of complex fractionated atrial electrogram (CFAE) ablation in addition to circumferential

pulmonary vein ablation and linear ablation: BOCA study. *Circ Arrhythmia Electrophysiol*. 2015, DOI: 101161/CIRCEP114002504.

- [46] Rappel W-J, Zaman JAB, Narayan SM. Mechanisms for the termination of atrial fibrillation by localized ablation: Computational and clinical studies. *Circ Arrhythmia Electrophysiol*. 2015; [Epub ahead of print].
- [47] Narayan SM, Baykaner T, Clopton P, Schricker A, Lalani G, Krummen DE, Shivkumar K, Miller JM. Ablation of rotor and focal sources reduces late recurrence of atrial fibrillation compared to trigger ablation alone. *J Am Coll Cardiol*. 2014;63:1761–1768.
- [48] Lin T, Kuck K-H, Ouyang F, Tilz RR. First in-human robotic rotor ablation for atrial fibrillation. *Eur Heart J*. 2014;35:1432.
- [49] Miller JM, Kowal RC, Swarup V, Daubert JP, Daoud EG, Day JD, Ellenbogen KA, Hummel JD, Baykaner T, Krummen DE, Narayan SM, Reddy VY, Shivkumar K, Steinberg JS, Wheelan KR. Initial independent outcomes from focal impulse and rotor modulation ablation for atrial fibrillation: Multicenter FIRM registry. J Cardiovasc Electrophysiol. 2014;25:921–929.
- [50] Rashid H, Sweeney A. Approaches for focal impulse and rotor mapping in complex patients: A US private practice perspective. *J Innov Card Rhythm Manag.* 2015;6:2193–2198.
- [51] Sommer P, Kircher S, Rolf S, John S, Arya A. Successful repeat catheter ablation of recurrent longstanding persistent atrial fibrillation with rotor elimination as the procedural endpoint: A case series short title: Rotor elimination as endpoint for AF ablations. *J Cardiovasc Electrophysiol*. 2015, DOI: 101111/jce.12874.
- [52] Tomassoni G, Duggal S, Muir M, Hutchins L, Turner K, Mcloney ANNM, Hesselson A. Long-term follow-up of FIRM-guided ablation of atrial fibrillation: A single-center experience. J Innov Card Rhythm Manag. 2015;6:2145–2151.
- [53] Foreman JR, Padanilam BJ, Olson JA, Nair GV, Prystowsky EN. Single center experience with FIRM ablation: A case series of 125 patients. *Heart Rhythm*. 2015;12:S118–S119.
- [54] Benharash P, Buch E, Frank P, Share M, Tung R, Shivkumar K, Mandapati R. Quantitative analysis of localized sources identified by focal impulse and rotor modulation mapping in atrial fibrillation. *Circ Arrhythmia Electrophysiol.* 2015;8:554–562.
- [55] Jalife J, Filgueiras-Rama D, Berenfeld O. Letter by Jalife et al.regarding article, "Quantitative analysis of localized sources identified by focal impulse and rotor modulation mapping in atrial fibrillation" nothing. *Circ Arrhythmia Electrophysiol*. 2015;8:1296–1298.
- [56] Narayan SM, Krummen DE, Rappel W-J. Clinical mapping approach to diagnose electrical rotors and focal impulse sources for human atrial fibrillation. *J Cardiovasc Electrophysiol*. 2012a;23:447–454.
- [57] Ghoraani B, Dalvi R, Gizurarson S, Das M, Ha A, Suszko A, Krishnan S, Chauhan VS. Localized rotational activation in the left atrium during human atrial fibrillation: Relationship to complex fractionated atrial electrograms and low- voltage zones. *Heart Rhythm*. 2013;10:1830–1838.
- [58] Lin Y-J, Lo M-T, Lin C, Chang S-L, Lo L-W, Hu Y-F, Hsieh W-H, Chang H-Y, Lin W-Y, Chung F-P, Liao J-N, Chen Y-Y, Hanafy D, Huang NE, Chen S-A. Prevalence, characteristics, mapping, and catheter ablation of potential rotors in nonparoxysmal atrial fibrillation. *Circ Arrhythm Electrophysiol*. 2013;6:851–858.
- [59] Walters TE, Lee G, Morris G, Spence S, Larobina M, Atkinson V, Antippa P, Goldblatt J, Royse A, O'Keefe M, Sanders P, Morton JB, Kistler PM, Kalman JM. Temporal stability of rotors and atrial activation patterns in persistent human atrial fibrillation: A high-density epicardial mapping study of prolonged recordings. *JACC Clin Electrophysiol*. 2015;1:14–24.
- [60] Cuculich PS, Wang Y, Lindsay BD, Faddis MN, Schuessler RB, Damiano RJ, Li L, Rudy Y. Noninvasive characterization of epicardial activation in humans with diverse atrial fibrillation patterns. *Circulation*. 2010;122:1364–1372.
- [61] Rodrigo M, Guillem MS, Climent AM, Pedrón-Torrecilla J, Liberos A, Millet J, Fernández-Avilés F, Atienza F, Berenfeld O. Body surface localization of left and right atrial high-frequency rotors in atrial fibrillation patients: A clinical- computational study. *Heart Rhythm.* 2014;11:1584–1591.
- [62] Zaman JAB, Narayan SM. Ablation of atrial fibrillation. How can less be more? *Circ Arrhythm Electrophysiol*. 2015.
- [63] Katritsis DG, Pokushalov E, Romanov A, Giazitzoglou E, Siontis GCM, Po SS, Camm AJ, Ioannidis JP. Autonomic denervation added to pulmonary vein isolation for paroxysmal atrial fibrillation: A randomized clinical trial. *J Am Coll Cardiol*. 2013;62:2318–2325.
- [64] Rolf S, Kircher S, Arya A, Eitel C, Sommer P, Richter S, Gaspar T, Bollmann A, Altmann D, Piedra C, Hindricks G, Piorkowski C. Tailored atrial substrate modification based on low-voltage areas in catheter ablation of atrial fibrillation. *Circ Arrhythm Electrophysiol*. 2014, DOI: 101161/CIRCEP113001251.
- [65] Atienza F, Almendral J, Ormaetxe JM, Moya Á, Martínez-Alday JD, Hernández-Madrid A, Castellanos E, Arribas F, Arias MÁ, Tercedor L, Peinado R, Arcocha MF, Ortiz M, Martínez-Alzamora N, Arenal Á, Fernández-Avilés F, Jalife J. Comparison of radiofrequency catheter ablation of drivers and circumferential pulmonary vein isolation in atrial fibrillation. J Am Coll Cardiol. 2014;64:2455–2467.
- [66] Marrouche NF, Wilber D, Hindricks G, Jais P, Akoum N, Marchlinski F, Kholmovski E, Burgon N, Hu N, Mont L, Deneke T, Duytschaever M, Neumann T, Mansour M, Mahnkopf C, Herweg B, Daoud E, Wissner E, Bansmann P, Brachmann J. Association of atrial tissue fibrosis identified by delayed enhancement MRI and atrial fibrillation catheter ablation: The DECAAF study. *Jama*. 2014;311:498–506.

- [67] Kenigsberg DN, Martin N, Lim HW, Kowalski M, Ellenbogen KA. Quantification of the cryoablation zone demarcated by pre- and postprocedural electroanatomic mapping in patients with atrial fibrillation using the 28-mm second- generation cryoballoon. *Heart Rhythm*. 2015;12:283–290.
- [68] Krummen DE, Swarup V, Narayan SM. The role of rotors in atrial fibrillation. *J Thorac Dis*. 2015;7:142–151.
- [69] Calkins H, Kuck KH, Cappato R, Brugada J, Camm AJ, Chen SA, Crijns HJ, Damiano Jr RJ, Davies DW, DiMarco J, Edgerton J, Ellenbogen K, Ezekowitz MD, Haines DE, Haissaguerre M, Hindricks G, Iesaka Y, Jackman W, Jalife J, Jais P, Kalman J, Keane D, Kim YH, Kirchhof P, Klein G, Kottkamp H, Kumagai K, Lindsay BD, Mansour M, Marchlinski FE, McCarthy PM, Mont JL, Morady F, Nademanee K, Nakagawa H, Natale A, Nattel S, Packer DL, Pappone C, Prystowsky E, Raviele A, Reddy V, Ruskin JN, Shemin RJ, Tsao HM, Wilber D. Heart Rhythm Society Task Force on Catheter and Surgical Ablation of Atrial Fibrillation. 2012 HRS/EHRA/ECAS expert consensus statement on catheter and surgical ablation of atrial fibrillation: Recommendations for patient selection, procedural techniques, patient management and follow-up, definitions, endpoints, and research trial design. *Europace*. 2012;14:528–606.